Randomised double-blind multicentre trial comparing bilateral subthalamic nucleus deep brain stimulation and bilateral globus pallidus deep brain stimulation for advanced Parkinson's disease

ISRCTN ISRCTN85542074
DOI https://doi.org/10.1186/ISRCTN85542074
Secondary identifying numbers WAR05-0203
Submission date
16/01/2007
Registration date
16/01/2007
Last edited
04/07/2016
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Nervous System Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
Patients with advanced Parkinson's disease often do not respond well to medication. When this is the case, deep brain stimulation (DBS) is a treatment option to improve stiffness, shaking and slowness. DBS is a type of surgery in which two electrodes are placed deep in the brain: one on each side of the brain. These electrodes transmit a current that relieves symptoms. This can be done in a brain area called the subthalamic nucleus (STN) or in an area called the globus pallidus (GPi). This study compares the effects of DBS of the STN with DBS of the GPi.

Who can participate?
Patients with Parkinson's disease suffering from uncontrollable involuntary movements, pain, or severe slowness can participate.

What does the study involve?
Patients are randomly allocated to receive DBS of either the STN or the GPi. Afterwards, they are followed extensively, for up to 5 years, to monitor the effects on motor symptoms, mental status, and behavior.

What are the possible benefits and risks of participating?
Both STN DBS and GPi DBS are already established treatment options for advanced PD. Risks of surgery include hemorrhage (bleeding), infection and malfunctioning of the equipment.

Where is the study run from?
The study is run from the Academic Medical Center, Amsterdam, The Netherlands. Four other centers in the Netherlands have participated

When is the study starting and how long is it expected to run for?
Patient recruitment ran from January 2007 until May 2012

Who is funding the study?
Stichting Internationaal Parkinson Fonds, Prinses Beatrix Fonds, and Parkinson Vereniging (Netherlands)

Who is the main contact?
Rob M A de Bie
r.m.debie@amc.uva.nl

Contact information

Dr Rob M A de Bie
Scientific

Academic Medical Center (AMC)
Department of Neurology, H2-236
PO Box 22660
Amsterdam
1100 DD
Netherlands

Email r.m.debie@amc.uva.nl

Study information

Study designRandomised controlled parallel-group double-blinded multicentre trial
Primary study designInterventional
Secondary study designRandomised parallel trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleRandomised double-blind multicentre trial comparing bilateral subthalamic nucleus deep brain stimulation and bilateral globus pallidus deep brain stimulation for advanced Parkinson's disease
Study acronymN-STAPS
Study objectivesAssuming that the effects on Parkinson's disease symptoms and dyskinesias, and the rates of procedure-related and device-related complications are almost equal, then continuous bilateral Globus Pallidus Deep Brain Stimulation (GPi DBS) may produce greater functional improvement than bilateral SubThalamic Nucleus (STN) stimulation in Parkinson's disease, because the latter is associated with long-term cognitive, mood, and behavioural problems.
Ethics approval(s)Medisch Ethische Commissie AMC, 17/05/2006, ref: MEC 06/084 # 07.17.0069. Last amendment approval received on 11/01/2007.
Health condition(s) or problem(s) studiedParkinson's disease
InterventionStereotactic bilateral implantation of DBS electrodes in the globus pallidus internus or the nucleus subthalamicus.
Intervention typeProcedure/Surgery
Primary outcome measureThe number of patients with significant cognitive, mood, and behavioural adverse effects and the off-on phase weighted Academic Medical Centre (AMC) Linear Disability Scale (functional improvement).

Significant cognitive, mood, and behavioural adverse effects are defined as worsening on three or more cognitive tests (based on the reliable change index), or the loss of professional activity/work/job, or the loss of an important relationship (e.g. marriage), or psychosis/depression/anxiety for a period of three months or longer.

Outcome measurements will be performed at baseline and 12 months after surgery.
Secondary outcome measuresSecondary outcome consists of:
1. Symptom scales (Unified Parkinson's Disease Rating Scale [UPDRS] motor, Clinical Dyskinesia Rating Scale [CDRS])
2. Activities of daily living scales (ADLS) and UPDRS Activity of Daily Living (ADL) scale
3. A quality of life questionnaire (Parkinsons Disease Quality of Life [PDQL])
4. Adverse effects
5. Medication use

Additionally, patients will undergo extensive neuropsychological and standardised psychiatric assessment.
Overall study start date01/01/2007
Completion date01/07/2012

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants128
Key inclusion criteriaIdiopathic Parkinson's disease and - despite optimal pharmacological treatment - at least one of the following symptoms: severe response fluctuations, dyskinesias, painful dystonias, or bradykinesia
Key exclusion criteria1. Age below 18 years
2. Previous functional stereotactic neurosurgery
3. Hoehn and Yahr stage five at the best moment during the day
4. A Mattis dementia rating scale score of less than 120
5. Psychosis, and contraindications for stereotactic neurosurgery such as a physical disorder making surgery hazardous (severe hypertension, blood coagulation disorder, severe dysphagia, or dysphasia)
Date of first enrolment01/01/2007
Date of final enrolment01/05/2012

Locations

Countries of recruitment

  • Netherlands

Study participating centre

Academic Medical Center (AMC)
Amsterdam
1100 DD
Netherlands

Sponsor information

Academic Medical Centre (AMC) (Netherlands)
Hospital/treatment centre

PO Box 22660
Amsterdam
1100 DD
Netherlands

Website http://www.amc.uva.nl/
ROR logo "ROR" https://ror.org/03t4gr691

Funders

Funder type

Research organisation

Prinses Beatrix Fonds (Netherlands)

No information available

Internationaal Parkinson Fonds (Netherlands)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/01/2013 Yes No
Results article results 23/02/2016 Yes No

Editorial Notes

04/07/2016: Publication reference added.

15/03/2010: this record was updated to include a second funder (details in the relevant section below). The overall trial end date was changed from 31/12/2009 to 01/07/2012.